DUBLIN, Feb. 4, 2016 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/mv7v2t/global_hematology) has announced the addition of the "Global Hematology Partnering 2010-2016: Deal trends, players and financials" company profile to their offering.
Global Hematology Partnering 2010 to 2016 provides the full collection of Hematology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Hematology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hematology deals.
The report presents financial deal terms values for Hematology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Hematology dealmaking trends.
Global Hematology Partnering 2010 to 2016 includes:
In Global Hematology Partnering 2010 to 2016, available deals and contracts are listed by:
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Hematology dealmaking
Chapter 3 - Financial deal terms for Hematology partnering
Chapter 4 - Leading Hematology deals and dealmakers
Chapter 5 - Hematology contract document directory
Chapter 6 - Hematology dealmaking by therapeutic target
For more information visit http://www.researchandmarkets.com/research/mv7v2t/global_hematology
Media Contact:
Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article